Skip to main content

Treating Indolent Lymphoma: Common and Rare Types

Recorded on: August 2, 2023

Click Here to Participate

Recorded on: August 2, 2023
1.0 CE Contact hour for nurses available until: March 11, 2025
1.0 CME Credit for physicians available until: September 11, 2024
1.0 CE Contact hour for nurse practitioners available until: August 31, 2024
ILNA Accredited
Non-interactive recorded webinar

Target Audience

This activity is intended for hematologist/oncologists, oncology nurses, and other healthcare professionals involved in the care of patients with lymphoma.

Educational Objectives

After completing this CE activity, the participant should be better able to:

  • Identify indolent lymphoma subtypes and explain the importance of an accurate diagnosis
  • Explain new and emerging treatments for follicular lymphoma, marginal zone, and Waldenstrom’s macroglobulinemia (WM)
  • Identify the interprofessional healthcare team’s role in managing a patient with a chronic blood cancer 
  • Describe common treatment side effects and patient management 
  • Review patient education and support resources 


Jonas Paludo, M.D. 
Assistant Professor of Medicine and Oncology
Mayo Clinic
Rochester, MN

Darci L. Zblewski, APRN, C.N.P
Department of Hematology-Lymphoma
Mayo Clinic
Rochester, MN

Continuing Education Information

Accreditation, Credit and Support

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society.  Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™.  
Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Registered Nursing Credit Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0 continuing education contact hours through the California Board of Registered Nursing.

Nurse Practitioner Credit Designation

AANP Accredited Stamp

This activity is approved for 1.00 contact hour(s) of continuing education (which includes 0.50 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 23086272. This activity was planned in accordance with AANP Accreditation Standards and Policies.


Interprofessional Continuing Education Credit

Interprofessional Continuing Education (IPCE) credit

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.


ILNA Recertification Points
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: Care Continuum (ONC, CBCN, CPHON, AOCNP), Oncology Nursing Practice (OCN), Professional Practice/Performance (BMTCN, AOCNP), Psychosocial Dimensions of Care (AOCNP, CPHON, ONC, CBCN), Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP), Treatment (OCN, CBCN, AOCNP, CPHON). 
Total points: 1.0*
*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.

There are no fees for participating in or receiving credit for this CE activity.

This activity is provided by The Leukemia & Lymphoma Society and Medical Learning Institute, Inc., in collaboration with the International Waldenstrom's Macroglobulinemia Foundation.

There is no commercial support associated with this CE activity.


For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at